This morning, Johnson & Johnson shared its 2024 second quarter earnings report.
Since its founding in 1886 the company has been committed to innovation—today, more than 130,000 employees across the globe work to deliver solutions for patients around the world and to help profoundly impact health for humanity.
“Johnson & Johnson’s second quarter performance was marked by numerous clinical and regulatory milestones that address some of the most complex healthcare challenges facing patients worldwide,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson.
“Financial performance for the quarter was solid, demonstrating the breadth and diversification of our business and enabling us to meet and beat expectations on the top and bottom line,” says Wolk. “We continue to deploy capital that advances our business by investing in R&D and executing strategic acquisitions that fortify our Innovative Medicine and MedTech portfolios, positioning us to deliver long-term sustainable growth.”
For more details about the company’s 2024 second quarter results and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.
Johnson & Johnson’s 2024 second quarter earnings
Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.
